Open an account

Bioventus

BVS · NASDAQ

$13.95+$0.46 (+3.41%)TodayMarket closed ·
Prev close $13.49

About BVS

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 930 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

Employees
940
Headquarters
Durham, North Carolina
Listed
Feb 11, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
bioventus.com

BVS key statistics

Market cap
1.17B
Price-earnings ratio
17.52
Dividend yield
—
Average volume
381.70K
Volume
331.29K
Open price
$13.64
High today
$14.00
Low today
$13.60
52 Week high
$15.89
52 Week low
$6.47

Bioventus (BVS) at a glance

Bioventus (BVS) last traded at $13.95, with a market cap of 1.17B and a price-to-earnings ratio of 17.52.

Today the stock has traded between $13.60 and $14.00. The current price is 2.6% above the day's low and 0.4% below its high.

Volume so far is 331.29K shares, in line with the average of 381.70K shares a day.

Over the past year Bioventus has ranged from $6.47 to $15.89, and now sits 79% of the way up that range.

Bioventus met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.22 per share against an estimate of $0.2182.

The average analyst price target is $17.95, 28.7% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $17.95
Low
$15.15
Now
$13.95
High
$19.95

BVS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 72.4% on average.

  1. Q3 FY24: reported $0.06 per share against an estimate of $0.0303
  2. Q4 FY24: reported $0.15 per share against an estimate of $0.0842
  3. Q1 FY25: reported $0.08 per share against an estimate of $0.0236
  4. Q2 FY25: reported $0.21 per share against an estimate of $0.2121
  5. Q3 FY25: reported $0.15 per share against an estimate of $0.1162
  6. Q4 FY25: reported $0.24 per share against an estimate of $0.2188
  7. Q1 FY26: reported $0.15 per share against an estimate of $0.0985
  8. Q2 FY26: reported $0.22 per share against an estimate of $0.2182

BVS news

  • Caroline Ryan

    Deal Dispatch: Bending Spoons Acquires Airtable, Bain Capital Buys Gong Cha Global, Salad and Go Bankruptcy

  • Press releasePRNewswire

    Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releasePRNewswire

    The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

  • Press releasePRNewswire

    Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

  • Preview: Bioventus's Earnings

  • Press releasePRNewswire

    HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

  • Press releaseBusiness Wire

    Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights

  • Press releaseGlobe Newswire

    Bioventus Reports Second Quarter Financial Results

Similar companies

Companies in the same industry as Bioventus

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.